Latest Breaking News On - Associated professional sleep societies - Page 9 : comparemela.com

HARMONY BIOSCIENCES ANNOUNCES POSITIVE PHASE 2 SIGNAL DETECTION STUDY EVALUATING PITOLISANT FOR EXCESSIVE DAYTIME SLEEPINESS IN PRADER-WILLI SYNDROME AT SLEEP 2023

/PRNewswire/ Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative.

United statesKumar budurSusan hedstromLuis sanayPaige rivardFoundation for prader willi researchParagon biosciencesResearch symposiumUnited states national convention in orlandoPrnewswire harmony biosciences holdings incDrug administrationExchange commissionPrader willi syndrome association united statesBiosciences holdingsAnnual meetingAssociated professional sleep societies

Harmony Biosciences (HRMY) Reports Positive Phase 2 Signal Detection Study Data

Harmony Biosciences (HRMY) Reports Positive Phase 2 Signal Detection Study Data
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSusan hedstromKumar budurPaige rivardPrader willi syndrome associationUnited states national conventionHarmony biosciences holdings incResearch symposiumFoundation for prader willi researchBiosciences holdingsAnnual meetingAssociated professional sleep societiesEpworth sleepiness scaleChief medical officerExecutive directorPrader willi research

Dr Dayna Johnson: Mindfulness Can Help Facilitate Better Sleep and Health Outcomes

Dayna Johnson, PhD, MPH, MSW, MS, the Rollins School of Public Health at Emory University, discusses principal findings from the analysis of a 35-day sleep intervention study that utilized a mobile mindfulness app to manage stress and anxiety combined with healthy sleep practices.

Dayna johnsonProgram committeeRollins schoolPublic healthEmory universityMindfulness interventionImprove sleepDiverse sampleResults fromPilot feasibilityAssociated professional sleep societiesInclusion leadershipSleep latency

Suven Life Sciences : June 03, 2023Suven announces two poster presentations from the phase-2 (PoC) study on samelisant (SUVN-G3031)

Suven Life Sciences announces two poster presentations including patient baseline characteristics and demographics from the phase-2 Proof of Concept study on samelisant at. | June 3, 2023

United statesResearch societyAmerican academy of sleep medicineSuven life sciencesOur companyAbout sleepAssociated professional sleep societiesAmerican academySleep medicineSleep research societyMajor depressive disorderAttention deficient hyperactivity disorderLife sciencesSuven life sciences limited stock exchangePress releaseAmelisant 530239 ine495b01038

Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023

Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Nichol ochsnerJennifer arcureChristopher drakeRene braeckmanChristal mickleExchange commissionEuropean medicines agencyHypersomnia foundationDrug administrationCorium incClinical developmentHenry ford healthCompany early access programUs drug enforcement agencyZevra therapeutics incWall street